Int J Radiat Oncol Biol Phys 2020 Sep 11
Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain.
ABSTRACT
PURPOSE
As part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) after hypofractionated radiation therapy, data from published reports (PubMed indexed 1995-2018) were pooled to identify dosimetric and clinical predictors of radiation-induced brain toxicity after single-fraction stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (fSRS).
METHODS AND MATERIALS
Eligible studies provided NTCPs for the endpoints of radionecrosis, edema, or symptoms after cranial SRS/fSRS and quantitative dose-volume metrics. Studies of patients with only glioma, meningioma, vestibular schwannoma, or brainstem targets were excluded. The data summary and analyses focused on arteriovenous malformations (AVM) and brain metastases.
RESULTS
Data from 51 reports are summarized. There was wide variability in reported rates of radionecrosis. Available data for SRS/fSRS for brain metastases were more amenable to NTCP modeling than AVM data. In the setting of brain metastases, SRS/fSRS-associated radionecrosis can be difficult to differentiate from tumor progression. For single-fraction SRS to brain metastases, tissue volumes (including target volumes) receiving 12 Gy (V12) of 5 cm, 10 cm, or >15 cm were associated with risks of symptomatic radionecrosis of approximately 10%, 15%, and 20%, respectively. SRS for AVM was associated with modestly lower rates of symptomatic radionecrosis for equivalent V12. For brain metastases, brain plus target volume V20 (3-fractions) or V24 (5-fractions) <20 cm was associated with <10% risk of any necrosis or edema, and <4% risk of radionecrosis requiring resection.
CONCLUSIONS
The risk of radionecrosis after SRS and fSRS can be modeled as a function of dose and volume treated. The use of fSRS appears to reduce risks of radionecrosis for larger treatment volumes relative to SRS. More standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses that can refine predictive models of brain toxicity risks.
Related Questions
Should it include the entire brain (normal brain + target) or just the normal brain (brain - target)? How does the V10 or V12 constraint change ...
New answer by Radiation Oncologist at SSM Cancer Center/St Louis CyberKnife (April 4, 2022)
Milano et al., as part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy investigating normal tissue complication probabili...
Would you dose escalate areas of regrowth or boost the entire cavity?
New answer by Radiation Oncologist at Icahn School of Medicine at Mount Sinai (September 20, 2023)
I would likely recommend discussing the possibility of a re-resection with a neurosurgeon as the initial step. If re-resection is not a viable option, my inclination would be ...
If a patient has a limited number of brain metastases (e.g., <3 total) but the additive volume of these intracranial metastases is high (e.g., each...
New comment by Radiation Oncologist at Mallory Radiotherapy, PLLC ( November 3, 2024)
With the exception of small cell lung cancer, I agree and would avoid whole brain radiation at all costs. There is an unfortunate practice pattern I have seen where whole brai...